Stock Mountie

Las Vegas From Home.com Entertainment Inc.: Real Vegas Casino Surpasses 100,000 Monthly Active Users on Facebook

Ku6 Media ( KUTV ) Announces Partnership with Kaixin001

Ku6 Media Announces Partnership with Kaixin001

BEIJING, May 24, 2012 /PRNewswire-Asia/ — Ku6 Media Co., Ltd. (“Ku6 Media” or the “Company”, Nasdaq: KUTV), a leading internet video company in China, focusing on User Generated Content (UGC), today announced that it has entered into an agreement with famous Chinese SNS website Kaixin001.com (“Kaixin001″).

Pursuant to the agreement, Ku6 Media, as the video hosting provider, is assisting Kaixin001 to add a brand new video sharing function by supplying technology support to all video uploading activities on Kaixin001.  Users on Kaixin001 will enjoy a one-stop service that enables them to upload, store and share their videos without leaving the website.  Meanwhile, users on Ku6 Media’s platform can share the videos with their friends on Kaixin001 by only one click.

Mr. Jeff Shi, Chief Executive Officer of Ku6 Media, commented, “We are very pleased with the cooperation with Kaixin001.  We believe our cooperation can help enlarging Ku6′s user base as well as richening our users’ online experience.  We also hope our videos and service can bring users on Kaixin001 more fulfilling experiences and more joy.”

Mr. Binghao Cheng, Chief Executive Officer of Kaixin001, added, “We are very excited about partnering up with Ku6 Media.  Our video sharing function is an important feature we have launched recently.  We believe it will enhance our user experience by bringing them abundant video content and also by providing a great platform for them to share their original videos.”

About Kaixin001.com

Kaixin001.com, founded in March 2008, is one of the leading and most influential social networking websites in China.  It locks on people who create social wealth and mainstream culture as core users; moreover, it has always devoted itself in offering a real and relaxed interactive platform for Chinese net citizen by exploring and satisfying users’ needs, improving users’ experience and keeping innovation on technology and products.  In general, Kaixin001.com provides rich and useful social tools, including diary, photo album, note, repast, and social game etc, which help users to easily communicate and share information with family members, friends, classmates and colleagues.

About Ku6 Media Co., Ltd.

Ku6 Media Co., Ltd. (KUTV) is a leading internet video company in China, focusing on User Generated Content (UGC).  Through its premier online brand and online video website, www.ku6.com, Ku6 Media provides online video upload and sharing service, video reports, information and entertainment in China.  For more information about Ku6 Media, please visit http://ir.ku6.com.

Safe Harbor Statement

This news release contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by terminology such as “believes,” “could,” “expects,” “may,” “might,” “should,” “will,” or “would,” and by similar statements. Forward-looking statements are not historical facts, but instead represent only the Company’s beliefs regarding future events, many of which, by their nature, are inherently uncertain and outside of its control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Some of the risks and important factors that could affect the Company’s future results and financial condition include: continued competitive pressures in China’s internet video portal market; changes in technology and consumer demand in this market; the risk that Ku6 Media may not be able to control its expenses in the future; regulatory changes in China with respect to the operations of internet video portal websites; the success of Ku6 Media’s ability to sell advertising and other services on its websites; and other risks outlined in the Company’s filings with the Securities and Exchange Commission, including the Company’s annual report on Form 20-F. Ku6 Media does not undertake any obligation to update this forward-looking information, except as required under law

Stornoway Announces $28.4M Renard Pre-Development Capital Program

Mounties Bounce Play ..Edgewater Announces Definitive Joint Venture Agreement With Kinross

ECOtality ( ECTY ) Reports Record First Quarter 2012 Results ,Revenue up 215% to Record $13.7 Million, Driving Record Net Income of $1.2 Million

SAN FRANCISCO–(BUSINESS WIRE)–

ECOtality,       Inc. (NASDAQ:ECTY – News), a leader in clean electric transportation and       storage technologies, reported financial results for the first quarter       ended March 31, 2012.

Q1 2012 Summary of Financial Results

Revenue in the first quarter of 2012 increased 215% to a record $13.7       million, as compared to $4.3 million in the same year-ago quarter. The       increase in revenue was largely attributed to the continued roll out of       network infrastructure for the EV Project and by a Blink^®network licensing agreement. The EV Project is a public-private       partnership with the Department of Energy that seeks to develop,       implement and study techniques for optimizing the deployment of a       commercially viable EV charging infrastructure.

The first quarter of 2012 represented the company’s first profitable       quarter, which was driven primarily by EV Project revenue and a Blink^®network licensing agreement. Net income in the first quarter of 2012 was       $1.2 million or $0.04 per basic and diluted share, as compared to a net       loss of $6.8 million or $(0.51) per basic and diluted share in the same       year-ago quarter.

Combined cash, restricted cash and cash equivalents at March 31, 2012       totaled $4.5 million, as compared to $10.2 million at December 31, 2011.       The decrease in cash was primarily attributed to the rapid increase in       both the production and installation of Blink^® DC Fast       Chargers required for the EV Project.

Q1 2012 Operational Highlights

•         Approximately 1,100 Blink^® chargers were installed during         the quarter, bringing the total number of charging stations to         approximately 6,700, and maintaining the Blink^® network as         the largest connected electric vehicle (EV) charging network in the         world.
•         The Blink^® network has delivered in total more than 5,000         megawatt-hours to EV drivers, who generated nearly 23 million miles of         data for the EV Project.
•         Signed a $5 million licensing agreement with ABB Technology Ventures         Ltd to utilize the Blink^® electric vehicle charging network.
•         ABB made a $5 million follow-on investment in the form of a         convertible note due in 2015.
•         Received the Bloomberg New Energy Pioneer Award, which was presented         to the top 10 companies around the world that are “forever changing         the energy landscape.” In addition, the company’s Blink^®Level 2 charger won an Edison Award, “honoring the best in innovation         and excellence in the development of new products and services.”
• Partnered with Regency Centers to install approximately 40 Blink^®electric vehicle charging stations at 19 Regency locations nationwide.
•         Partnered with South Lake Union Discovery Center, operated by Vulcan         Real Estate, to install the first Blink^® DC Fast Charger in         the Seattle area, while also installing the company’s first DC Fast         Charger in Northern California at Volkswagen Group of America         Electronics Research Laboratory.
•         Strengthened management team with the appointments of Murray Jones as         chief operating officer, Paul Gordon as chief technology officer and         Martin Felli as vice president and general counsel.

Management Commentary

“We are pleased by our record first quarter results, in terms of both       profitability and operational performance,” said Jonathan Read,       president and CEO of ECOtality. “These achievements were driven in part       by our new licensing agreement with ABB. Its follow-on investment, along       with our recent management hires, ideally positions ECOtality for the       successful execution of the EV Project and the national rollout of the       Blink^® network.

“As the project manager of the EV Project, the largest EV research       project ever undertaken, ECOtality continues to collect valuable insight       into how to more efficiently and effectively build-out a national EV       infrastructure. As we move forward in 2012, we look forward to       accelerating the roll-out of our national Blink^® charging       network, while further developing and testing numerous opportunities to       monetize this network, as well as deriving continued benefits from the       EV Project.”

About ECOtality, Inc.

ECOtality, Inc. (NASDAQ:ECTY – News), headquartered in San Francisco,       California, is a leader in clean electric transportation and storage       technologies. Through innovation, acquisitions, and strategic       partnerships, ECOtality accelerates the market applicability of advanced       electric technologies to replace carbon-based fuels. For more       information about ECOtality, Inc., please visit www.ecotality.com.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of       Section 27A of the Securities Act of 1933, as amended, and Section 21E       of the Securities Exchange Act of 1934, as amended. All forward-looking       statements are inherently uncertain as they are based on current       expectations and assumptions concerning future events or future       performance of the company. Readers are cautioned not to place undue       reliance on these forward-looking statements, which are only predictions       and speak only as of the date hereof. In evaluating such statements,       prospective investors should review carefully various risks and       uncertainties identified in this release and matters set in the       company’s SEC filings. These risks and uncertainties could cause the       Company’s actual results to differ materially from those indicated in       the forward-looking statements.

Peregrine Announces Positive Top-Line Data From Randomized

Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung Cancer

Bavituximab Plus Chemotherapy Demonstrates Doubling of Overall Response Rates Versus Chemotherapy Alone; 50% Improvement in Progression-Free Survival and Overall Survival Trends Support Phase III Development

TUSTIN, CA–(Marketwire -05/21/12)-  Peregrine Pharmaceuticals, Inc. (PPHM) today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase IIb trial evaluating two dose levels of bavituximab plus docetaxel versus docetaxel plus placebo (control arm) in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial showed a doubling of overall response rates (ORR), the primary endpoint, and an improvement in progression-free survival (PFS), a secondary endpoint, in patients treated in the bavituximab-containing arms when compared to the control arm. Another secondary endpoint, median overall survival (OS), in the control arm has already been determined at less than 6 months, while the median has not been reached in either bavituximab-containing arm.

Based on independent radiology reviews and current status of patients, top-line data from the trial are as follows:

 
----------------------------------------------------------------------------
                                                     Bavituximab Bavituximab
                                           Placebo    (1 mg/kg)   (3 mg/kg)
Treatment Arm                                plus        plus        plus
                                          docetaxel   docetaxel   docetaxel
----------------------------------------------------------------------------
Overall Response Rate (ORR)                  7.9%       15.0%       17.9%
----------------------------------------------------------------------------
Median Progression-Free Survival (PFS)    3.0 months  4.2 months  4.5 months
----------------------------------------------------------------------------

“The compelling results from this rigorously designed trial clearly demonstrate that the combination of bavituximab and docetaxel is more active than docetaxel alone in treating second-line non-small cell lung cancer. We saw twice as many patients demonstrating an objective tumor response, increased progression-free survival, and already promising survival trends in this refractory setting. These results give us a high level of confidence as we begin planning for Phase III development in this indication,” said Joseph Shan, vice president, clinical and regulatory affairs at Peregrine. “We now look forward with heightened enthusiasm to several clinical data points coming this year, including overall survival results from this and potentially two other randomized Phase II trials, as well as data from four ongoing investigator-sponsored trials evaluating new treatment combinations in various cancers.”

Based on the review of safety and efficacy of this trial conducted by an independent Data Monitoring Committee, no significant safety issues or concerns were identified when comparing the bavituximab containing arms with the docetaxel alone arm.

This trial enrolled 121 patients with second-line Stage IIIb or IV (TNM Edition 7) non-squamous NSCLC following one prior chemotherapy regimen and were equally randomized to 1 of the 3 treatment arms, with 117 patients included in the top-line analysis. Tumor responses were determined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST 1.1). Patients received up to 6 cycles of docetaxel (75mg/m2) plus either placebo, 1 mg/kg bavituximab, or 3 mg/kg bavituximab until disease progression.

“After working on over 17 drug approvals, it is data like this that continues to energize and excite me. These robust data will be important in discussions with the FDA regarding advancing bavituximab’s clinical development in second-line non-small cell lung cancer,” said Robert Garnick, PhD, head of regulatory affairs at Peregrine. “We look forward to working closely with the FDA to identify the most efficient path toward commercialization for this promising candidate in this indication where new therapies are desperately needed.”

According to the American Cancer Society, lung cancer is the second most commonly diagnosed cancer in the U.S., with approximately 226,160 new cases and 160,340 deaths each year, representing approximately 28% of all cancer deaths. NSCLC is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases. Unfortunately, the five-year survival rate for NSCLC patients is only 1%.

“These data are a significant validation of the clinical potential of bavituximab for patients with few effective treatment options. These data will be instrumental in planning Phase III development in NSCLC and we are excited to share these data as part of ongoing partnering discussions,” said Steven W. King, president and chief executive officer of Peregrine. “We look forward to sharing even more clinical data points this year from all seven bavituximab studies aimed at highlighting the broad therapeutic potential of bavituximab across multiple oncology indications and treatment combinations thus potentially building even more value in the program.”

About Bavituximab Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company’s PS technology platform and is currently being tested in seven clinical trials including three randomized Phase II trials in front-line and second-line non-small cell lung cancer, front-line pancreatic cancer and four investigator-sponsored trials (ISTs) in additional oncology indications.

PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but “flips” and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and infectious diseases with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the overall survival data together with the above reported data may not support registration filings with the U.S. Food and Drug Administration (“FDA”), the risk that results from the other randomized Phase II trial will not be consistent with results experienced in the earlier single-arm Phase II trial or support registration filings with the FDA, and the risk that Peregrine may not have or raise adequate financial resources to complete the planned clinical programs. Factors that could cause actual results to differ materially or otherwise adversely impact the company’s ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2011 and the quarterly report on Form 10-Q for the quarter ended January 31, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Osiris stem cell therapy approved in Canada

NEW YORK (AP) — Osiris Therapeutics Inc. said Thursday that Canadian regulators approved its stem cell therapy Prochymal, which is intended to treat a deadly side effect of bone marrow transplants.

The company said Health Canada approved Prochymal for use against graft vs. host disease, a condition in which transplanted bone marrow cells attack the body of the patient. Prochymal is approved for use in children who are not responding to steroid therapy. Osiris said about 80 percent of child who contract graft vs. host disease die.

Osiris is still running clinical trials of Prochymal to support full marketing approval, but the drug was granted a type of conditional approval because of the lack of effective treatments for graft vs. host disease. Osiris is required to run additional studies to confirm the treatment works.

Marketing of Prochymal has not been approved in the U.S., but patients can get the treatment under certain conditions. The Food and Drug Administration allows the use of Prochymal in treatment of both adults and children with graft vs. host disease after steroids have failed.

Osiris, based in Columbia, Md., was developing Prochymal and a second stem cell treatment, Chondrogen, as part of a partnership with Genzyme, a unit of French drugmaker Sanofi. But in February Sanofi said it discontinued late-stage testing of Prochymal. Osiris said it believes Sanofi has terminated the collaboration and that it should regain all rights to Prochymal. Osiris said Sanofi disagrees and the companies are discussing their status.

Prochymal is also being studied as a treatment for Crohn’s disease and other conditions.

Shares of Osiris Therapeutics dipped 5 cents to $5.26 on Thursday and climbed 74 cents, or 14.1 percent, to $6 in after-hours trading.

RepliCel Life Sciences Inc Takes Next Steps for Phase IIb Dosing Trial

Pansoft Signs Definitive Agreement With Timesway Group Limited

Pansoft Signs Definitive Agreement With Timesway Group Limited in “Going Private” Transaction and Raises Acquisition Price to $4.15 per Share

JINAN, CHINA–(Marketwire -05/17/12)-  Pansoft Company Limited (PSOF) (“Pansoft” or the “Company”), a leading ERP software service provider for the oil and gas industry in China, today announced that the Company entered into an agreement and plan of merger (the “Agreement”) on May 16, 2012 with Timesway Group Limited, a company limited by shares incorporated under the laws of the British Virgin Islands (the “Parent”), Genius Choice Capital Limited, a company limited by shares incorporated under the laws of the British Virgin Islands and a direct wholly owned subsidiary of Parent (the “Merger Sub”). Timesway Group Limited is controlled by Chairman Hugh Wang and CEO Guoqiang Lin and had voting power over 63% of the Company’s voting securities as of June 30, 2011. Timesway Group Limited intends to finance the merger and the other transactions contemplated by a bank loan raised in Hong Kong, China.

Pursuant to the Agreement, (i) upon the terms and subject to the conditions set forth therein, at the effective time of the merger, upon the terms and subject to the conditions of this Agreement and in accordance with the BVI Companies Law, Merger Sub shall be merged with and into the Company. Following the Merger, the Company shall continue as the surviving corporation and the separate corporate existence of Merger Sub shall cease, and (ii) each ordinary share, par value US$0.0059 per share, of the Company issued and outstanding immediately prior to the effective time of the merger (individually, a “Share” and collectively, the “Shares”) (other than Shares to be cancelled), shall be cancelled in exchange for the right to receive an amount in cash equal to US$4.15 per Share without interest. As of the effective time of the merger, all of the Shares shall no longer be outstanding and shall automatically be cancelled and shall cease to exist and the register of members of the Company will be updated accordingly. The $4.15 cash Per Share consideration, represents a 106.0% premium to the one-day pre-announcement price of $2.01 per share on January 6, 2012, the last trading day prior to the Company’s announcement on January 9, 2012 that it had received a “going private” proposal, representing a 10% increase from the $3.76 originally offered by Timesway on January 7, 2012.

The Company’s Board of Directors, acting upon the unanimous recommendation of the Special Committee consisting of independent Board members Paul Gillis, Samuel Shen, and Tony Luh, approved the Agreement and the merger contemplated in the Agreement and resolved to recommend that the Company’s shareholders vote to approve and adopt the Merger Agreement and the merger. The Special Committee, which is composed solely of directors unrelated to Parent, Merger Sub or any of the management members of the Company, negotiated the terms of the Merger Agreement with the assistance of its financial and legal advisors.

The merger contemplated in the Agreement is subject to the approval by an affirmative vote of shareholders representing a majority of the Shares present and voting in person or by proxy as a single class at a meeting of the Company’s shareholders which will be convened to consider the approval and adoption of the Agreement and the merger, as well as certain other customary closing conditions. If completed, the merger will result in the Company becoming a privately-held company and its Shares would no longer be listed on the NASDAQ Capital Market.

Duff & Phelps, LLC is serving as financial advisor to the Special Committee. Morgan, Lewis & Bockius, LLP as the Special Committee’s United States law counsel and Maples and Calder is serving as its British Virgin Islands law counsel.

Additional Information about the Transaction The Company will furnish to the Securities and Exchange Commission (the “SEC”) a report regarding the proposed merger, which will include the Merger Agreement and related documents. All parties desiring details regarding the proposed merger are urged to review these documents, which are available at the SEC’s website (http://www.sec.gov).

In connection with the proposed merger, the Company will prepare and mail a proxy statement to its shareholders. In addition, certain participants in the proposed merger will prepare and mail to the Company’s shareholders a Schedule 13E-3 transaction statement. These documents will be filed with or furnished to the SEC. INVESTORS AND SHAREHOLDERS ARE URGED TO READ CAREFULLY AND IN THEIR ENTIRETY THESE MATERIALS AND OTHER MATERIALS FILED WITH OR FURNISHED TO THE SEC WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY, THE PROPOSED MERGER AND RELATED MATTERS. In addition to receiving the proxy statement and Schedule 13E-3 transaction statement by mail, shareholders also will be able to obtain these documents, as well as other filings containing information about the Company, the proposed merger and related matters, without charge, from the SEC’s website (http://www.sec.gov) or at the SEC’s public reference room at 100 F Street, NE, Room 1580, Washington, D.C. 20549. In addition, these documents can be obtained, without charge, by contacting the Company at the following address and/or phone number:

Pansoft Company Limited 3/F Qilu Software Park Building, Hi-Tech Zone, Jinan, Shandong, People’s Republic of China 250101 Telephone:   86-531-88871166 begin_of_the_skype_highlighting            86-531-88871166     end_of_the_skype_highlighting

The Company and certain of its directors, executive officers and other members of management and employees may, under SEC rules, be deemed to be “participants” in the solicitation of proxies from our shareholders with respect to the proposed merger. Information regarding the persons who may be considered “participants” in the solicitation of proxies will be set forth in the proxy statement and Schedule 13E-3 transaction statement relating to the proposed merger when it is filed with the SEC. Additional information regarding the interests of such potential participants will be included in the proxy statement and Schedule 13E-3 transaction statement and the other relevant documents filed with the SEC when they become available.

This announcement is neither a solicitation of proxy, an offer to purchase nor a solicitation of an offer to sell any securities and it is not a substitute for any proxy statement or other filings that may be made with the SEC should the proposed merger proceed.

About Pansoft Company Limited Pansoft is a leading enterprise resource planning (“ERP”) software and professional services provider for the oil and gas industry in China. Its ERP software offers comprehensive solutions for various business operations including accounting, order processing, delivery, invoicing, inventory control, and customer relationship management. For more information, go to Pansoft’s website at http://www.pansoft.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 This press release contains forward-looking statements concerning Pansoft Company Limited, which include but are not limited to, statements regarding Pansoft’s ability to expand its service offerings and maintain leadership as a provider of ERP software and services for the oil and gas industry in China. The actual results may differ materially depending on a number of risk factors including but not limited to, the following: general economic and business conditions, development, shipment and market acceptance of products, additional competition from existing and new competitors, changes in technology or product techniques, the Company’s ability to successfully integrate acquisitions, its ability to repurchase shares, share-repurchase plans, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company’s reports filed with the Securities and Exchange Commission. Pansoft Company Limited undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this

Rosetta Genomics Achieves Major Commercial Milestone by Obtaining Medicare Coverage of miRview mets2 Assay

PHILADELPHIA, PA and REHOVOT, ISRAEL–(Marketwire -05/16/12)-  Rosetta Genomics Ltd. (ROSG), a leading developer and provider of microRNA-based molecular diagnostic tests, today announced that Novitas, the designated Medicare Administrative Contractor for the Company’s miRview® mets² assay, has informed Rosetta that it plans to cover this assay for all Medicare beneficiaries. MiRview® mets² accurately identifies the primary tumor of origin in primary and metastatic cancer including Cancer of Unknown or Uncertain Primary (“CUP”).

“This is a major commercial achievement for Rosetta Genomics as Medicare coverage is a critical step toward widespread commercial adoption and payment for our lead diagnostic assay, miRview® mets², and enables access to this clinically valuable test to Medicare patients. This decision is important not only because Medicare is the largest U.S. payor, covering a large percentage of the patients for whom miRview® mets² has been ordered historically and would be expected to be ordered in the future, but also because private payors often look to Medicare’s decisions when setting their own reimbursement policies,” noted Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics. “We are particularly pleased with how rapidly we obtained Medicare coverage, as we launched our direct selling effort in the U.S. just one year ago.

“The decision by Novitas to cover the miRview® mets² assay reflects the clinical importance of determining the tumor origin in hard-to-diagnose metastatic cancers and CUP. This is particularly important as new, targeted cancer treatments are developed for site-specific cancers. We believe that the miRview® mets² assay is an important tool that can improve the ability of physicians to accurately diagnose CUP in order to optimize treatment plans,” added Mr. Berlin.

The policy will cover the 45 million Medicare beneficiaries and will enable Rosetta to provide the miRview® mets2 assay for Medicare beneficiaries throughout the U.S. at no cost to the patient, thereby eliminating an adoption barrier for the physician ordering the test and for the patient. Novitas’ decision is based on the extensive body of clinical data published in peer-reviewed journals from clinical studies conducted internally as well as at leading institutions. Once the Novitas decision is finalized with respect to reimbursement level, we will focus our efforts on obtaining appropriate coverage and reimbursement from commercial payors.

“This coverage decision will allow all appropriate Medicare patients access to the miRview® mets² assay and further recognizes the value that our assays are delivering to physicians, payors and patients. We look forward to continuing our dialogue with Novitas, and to their final decision on reimbursement level within the coming weeks,” concluded Mr. Berlin.

About miRview® Products miRview® are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview® mets and miRview® mets² accurately identify the primary tumor type in primary and metastatic cancer including Cancer of Unknown Primary (CUP). miRview® squamous accurately identifies the squamous subtype of non-small cell lung cancer, which carries an increased risk of severe or fatal internal bleeding and poor response to treatment for certain therapies. miRview® meso diagnoses mesothelioma, a cancer connected to asbestos exposure. miRview® lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview® kidney accurately classifies the four most common kidney tumors: Clear Cell Renal Cell Carcinoma (RCC), Papillary RCC, Chromophobe RCC and Oncocytoma. miRview® tests are designed to provide objective diagnostic data; it is the treating physician’s responsibility to diagnose and administer the appropriate treatment. In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview® mets and miRview® mets² test, 60,000 from miRview® squamous, 60,000 from miRview® meso, 54,000 from miRview® kidney and more than 1 million patients worldwide from miRview® lung. The Company’s tests are offered directly by Rosetta Genomics in the U.S., and through distributors around the globe. For more information, please visit www.mirviewdx.com. Parties interested in ordering the test can contact Rosetta Genomics at  (215) 382-9000 begin_of_the_skype_highlighting            (215) 382-9000     end_of_the_skype_highlighting  ext. 309.

About Rosetta Genomics Rosetta Genomics develops and commercializes a full range of microRNA-based molecular diagnostics. Founded in 2000, the Company’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. The Company’s miRview® product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab. To learn more, please visit www.rosettagenomics.com.

Forward-Looking Statements Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the expectation that private-sector payors would look to Medicare’s decisions when setting their own reimbursement policies and that we will be able to obtain appropriate coverage and reimbursement from commercial payors, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta’s approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which may never lead to commercially accepted products or services; Rosetta’s ability to obtain, maintain and protect its intellectual property; Rosetta’s ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta’s need and ability to obtain additional funding to support its business activities; Rosetta’s dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta’s ability to successfully develop its products and services; Rosetta’s ability to obtain regulatory clearances or approvals that may be required for its products and services; the ability to obtain coverage and adequate payment from health insurers for the products and services comprising Rosetta’s technology; the ability to obtain a formal agreement for Medicare coverage and to maintain an equitable reimbursement valuation; competition from others using technology similar to Rosetta’s and others developing products for similar uses; Rosetta’s dependence on collaborators; and Rosetta’s short operating history; as well as those risks more fully discussed in the “Risk Factors” section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2011 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.